spacer
home > white papers > CRSF Label - Child-Resistant Blister Packs With Booklet Label - Faubel & Co. Nachfolger GmbH
WHITE PAPERS
logo_Faubel_&_C3.JPG

Faubel & Co. Nachfolger GmbH

phone +49 5661 7309-0
email info@faubel.de
web http://www.faubel.de
email Schwarzenberger Weg 45, 34212 Melsungen

CRSF Label - Child-Resistant Blister Packs With Booklet Label

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.

The project was primarily focused on the functionality of the packaging solution, including with regard to the integrity of the inner soft capsules. Due to different countries participating in the clinical trial, the objective was to achieve certification according to EU standard DIN 14375 and US standard 16 CFR § 1700.20 with the final concept as well as to accommodate more than 20 different languages. Despite the high requirements in terms of function and the standard, Faubel was anxious to provide an efficient packaging concept.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>


White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>


Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement